Studies associated with ontology term
MA:0002450   'body fluid or substance'
   
Navigate ontologies  


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Albers1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet
Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Attie2 metabolic panel
with high-fat high-sucrose diet
Glucose, HOMA-IR, HOMA-B. DO population both 4-26wks 2018
Attie2 hormone quantification
with high-fat high-sucrose diet
Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. DO population both 4-26wks 2018
Attie2 lipid profile
with high-fat high-sucrose diet
Triglyceride. DO population both 4-26wks 2018
Attie2 glucose tolerance
with high-fat high-sucrose diet
Area under curve. DO population both 4-26wks 2018
Attie2 biomarker quantification
with high-fat high-sucrose diet
Bile acids in feces. DO population both 4-26wks 2018
Auwerx1 glucose tolerance
with high-fat diet
Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 hormone quantification
with high-fat diet
Glucose post oral gavage: 0, 15, 30 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 metabolic panel
with high-fat diet
Enzymes, bile acid, proteins, creatinine, glucose, iron, lactate. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 lipid profile
with high-fat diet
Cholesterol, HDL, LDL, free fatty acids, triglyceride. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 cell signaling molecule detection
with high-fat diet
INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 complete blood count
with high-fat diet
RBC, hematocrit. BXD w/par   (57) m 8-29 wks 2016
Auwerx2 glucose tolerance
with high-fat diet
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. inbred w/CC8 both 8-21 wks 2021
Auwerx2 hormone quantification
with high-fat diet
Insulin levels following glucose post oral gavage: 0, 15, 30 min. inbred w/CC8 both 8-21 wks 2021
Auwerx2 metabolic panel
with high-fat diet
Enzymes, creatinine, iron, lactate, urea. inbred w/CC8 both 8-21 wks 2021
Auwerx2 lipid profile
with high-fat diet
Cholesterol, HDL, LDL, triglycerides, free fatty acids. inbred w/CC8 both 8-21 wks 2021
Bautz1 study archive Plasma lipids. Cholesterol, triglycerides. QTL population both 12-14wks 2013
Beamer2 study archive Bone morphology and strength, insulin-like growth factor 1. QTL population f 16wks 2001
Bennett3 alcohol quantification
with ethanol
Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. ILSXISS w/par   (74) both 8-14wks 2007
Bennett4 metabolic panel Plasma enzymes, creatinine, glucose, urea, metabolic health score. both 8-20wks 2021
Bennett4 lipid profile Cholesterol, non-esterified fatty acids, triglyceride. both 8-20wks 2021
Bennett4 biomarker quantification TMAO, choline, phosphocholine, glycerophosphocholine, betaine, carnitine. both 8-20wks 2021
Bennett4 hormone quantification Insulin, glucose:insulin ratio. both 8-20wks 2021
Berndt3 metabolite quantification Vitamin D concentration (serum). inbred   (18) m 11wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. inbred   (31) both 8-12wks 2010
Brockmann1 study archive Body, organ weights, litter size, abdominal fat, lipids, insulin, leptin. QTL population both 3-6wks 2009
Brugnara1 complete blood count Hematology. inbred   (10) both 8wks 2013
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. inbred   (10) both 8wks 2013
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno3 metabolic panel Glucose (plasma). 4h fast. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 complete blood count Hematology. CC diallel w/par   (62) both 8-16wks 2012
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. inbred   (38) both 8-10wks 2011
Chesler2 metabolic panel Clinical blood chemistry. 16h fast. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 complete blood count Hematology. CC diallel w/par   (62) both 7-15wks 2011
Chesler3 metabolic panel Clinical blood chemistry. 16h fast. CC pre w/par   (367) both 7-15wks 2011
Chesler3 complete blood count Hematology. CC pre w/par   (367) both 7-15wks 2011
Chesler6 study archive
with ethanol
Sensitivity to ethanol. Baseline and ethanol. QTL population both 9-34wks 2012
Cheverud1 glucose tolerance
with high-fat diet
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 lipid profile
with high-fat diet
Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 hormone quantification
with high-fat diet
Insulin, leptin. LGXSM w/par   (19) both 12-16wks 2004
Collins1 complete blood count Hematology. CC pre w/par   (139) m 10-14wks 2012
Cowell1 hormone quantification
with Staphylococcus aureus
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. inbred   (13) f 8wks 2012
Cowell1 in vitro assay
with Staphylococcus aureus
Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. inbred   (13) f 8wks 2012
Crabbe4 alcohol quantification
with ethanol
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
DiPetrillo2 urinalysis Microalbumin, creatinine, ratio. CC pre w/par   (163) m 10wks 2012
Donahue1 metabolic panel Thyroxine (serum). inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. inbred w/CC7   (30) both 15-16wks 2002
Donahue5 immune cell quantification White blood cell and immune cell differentials. B6.A consomic w/par   (22) both 7wks 2011
Donahue6 immune cell quantification White blood cell and immune cell differentials. B6.PWD consomic w/par   (28) both 7wks 2011
Donahue7 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.A consomic w/par   (22) both 9wks 2012
Donahue8 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.PWD consomic w/par   (28) both 9wks 2011
Donahue9 metabolic panel Clinical blood chemistry (serum). 4h fast. B6.PWD consomic w/par   (25) both 11wks 2011
Doorenbos1 study archive Urinalysis. Creatinine, microalbumin, body weight. QTL population m 8-10wks 2008
Eumorphia1 complete blood count Hematology. inbred   (8) both 12wks 2007
Eumorphia1 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. inbred   (8) both 12wks 2007
Eumorphia1 metabolic panel Clinical blood chemistry (plasma). Unknown fast. inbred   (8) both 12wks 2007
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. inbred   (4) both 12, 24, 52 wks 2008
Eumorphia7 immunoglobulin quantification Immunoglobulin concentrations (serum). inbred   (6) both 9-12wks 2008
Farmer1 study archive Colitis susceptibility, severity. Colon histopathology, body and spleen weight. QTL population both 6wks 2001
Gatti2 study archive Whole blood neutrophil count and white cell count. DO population both 10-12wks 2014
GMC06 metabolic panel Glucose, glycerol. 16h fast. inbred   (5) both 10-11wks 2020
GMC06 lipid profile Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. inbred   (5) both 10-11wks 2020
GMC11 glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. inbred w/CC8   (6) both 13-14wks 2020
GMC15 complete blood count Hematology. inbred w/CC8   (8) both 20-21wks 2020
GMC16 metabolic panel Clinical blood chemistry (plasma). No fast. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC16 lipid profile Cholesterol, triglycerides. No fast, plasma. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC20 immunoglobulin quantification Immunoglobulins (plasma). inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC20 autoantibody quantification Anti-DNA autoantibodies, rheumatoid factor. inbred w/CC8   (8) both 16-17, 20-21wks 2020
Gould1 drug and metabolite quantification
with lithium
Lithium concentration in brain tissue and blood serum after lithium (several doses). inbred   (11) m 7-8wks 2011
Gould2 drug and metabolite quantification
with nicotine
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. inbred   (8) m 8-12wks 2011
Graubert1 complete blood count
with ENU
Hematology. inbred   (20) both 9wks; 12-64wks 2006
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. inbred   (25) both 8-10wks 2012
Hadsell2 mineral quantification concentrations of various minerals in milk inbred   (31) f 14-20wks 2018
Hageman1 study archive eQTL, urinary albumin excretion using microarray. QTL population m 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
HMDPpheno5 complete blood count Hematology. HMDP   (83) m 16wks 2013
Ishimori1 study archive
with high-fat diet
Lipids, atherosclerosis lesions, parathyroid hormone after high-fat diet. QTL population f 20wks 2004
JaxCC1 urinalysis Microalbumin, creatinine, ratio. CC   (18) both various 2018
JaxCC1 hormone quantification Insulin (plasma). CC   (18) both various 2018
JaxCC1 complete blood count Hematology. CC   (18) both various 2018
JaxKOMP-EAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 8-18wks 2021
JaxKOMP-EAP urinalysis Microalbumin, creatinine, ratio. KOMP both 8-18wks 2021
JaxKOMP-EAP lipid profile Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. KOMP both 8-18wks 2021
JaxKOMP-EAP metabolic panel Clinical blood chemistry (plasma). No fast. KOMP both 8-18wks 2021
JaxKOMP-EAP complete blood count Hematology parameters. KOMP both 8-18wks 2021
JaxKOMP-EAP hormone quantification Insulin (plasma). KOMP both 8-18wks 2021
JaxKOMP-LAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 66-81wks 2021
JaxKOMP-LAP metabolic panel Clinical blood chemistry (plasma). No fast. KOMP both 66-81wks 2021
JaxKOMP-LAP complete blood count Hematology parameters. KOMP both 66-81wks 2021
Jaxpheno3 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred   (11) both 8, 16 wks 2006
Jaxpheno3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred   (11) both 8, 16 wks 2006
Jaxpheno4 complete blood count Hematology. inbred   (11) both 8, 16 wks 2006
Jaxpheno7 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). inbred   (6) m 10wks 2010
Justice2 complete blood count Hematology. inbred   (16) both 12-16wks 2002
Karst1 study archive Characterization of high-muscle-mass mice. QTL population both 3-10wks 2011
Kim1 study archive Glucose, insulin, body and fat pad weights. QTL population m 20-26wks 2001
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Lake1 complete blood count Hematology. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 metabolic panel Glucose, bilirubin, aspartate transaminase (plasma). 4h fast. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 lipid profile Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. B6.A consomic w/par   (23) both 7-11wks 2005
Lake2 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). B6.A consomic w/par   (23) both 8wks 2005
Leiter2 study archive Type 1 diabetes development study. QTL population f 14-40wks 2009
Li1 study archive
with western diet
Lipids, atherosclerosis lesion histopathology. High-fat, western-style diet. QTL population f 12wks 2008
Lyons1 study archive
with high-fat diet
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population m 16-18wks 2003
Lyons2 study archive
with high-fat diet
Lipids (plasma), bile, liver weight, gallbladder and gallstone histopathology. QTL population m 16-18wks 2003
Lyons3 study archive
with high-fat diet
Lipids, gallbladder and gallstone histopathology after high-fat diet. QTL population m 14-20wks 2004
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Nadeau2 metabolic panel
with high-fat high-sucrose diet
Glucose, insulin, insulin resistance after 16wks of high-fat high-sucrose diet. 16h fast. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau2 lipid profile
with high-fat high-sucrose diet
Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau3 hormone quantification
with high-fat high-sucrose diet
Insulin and insulin resistance after 16 wks of high-fat high-sucrose diet. Overnight fast. inbred   (2) m 21 wks 2016
Nadeau3 lipid profile
with high-fat high-sucrose diet
Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. inbred   (2) m 21 wks 2016
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Noll1 immunoglobulin quantification IgM, IgG1, IgG2a + IgG2c, IgG2b, IgG3, total IgG CC RIX   (46) f 8-12 wks of age 2020
Paigen1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen3 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen3 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. obesity mutants   (8) both 15-19wks 2000
Paigen3 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet obesity mutants   (8) both 15-19wks 2000
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Palmer3 metabolic panel Glucose (blood). Before and after 16h fast. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 metabolic panel Glucose (blood). Before and after 16h fast. F1 Tcf7l2   (30) both 7-14wks 2017
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters2 complete blood count Hematology. AXB BXA   (28) both 11wks 2004
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (30) both 26, 52, 78, 104 wks 2007
Peters5 study archive Complete blood count measures on fetuses, newborns. QTL population both fetus, newborn 2004
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Pitman1 study archive
with high-fat diet
Cholesterol (plasma) after high-fat diet (several timepoints). QTL population f 6-26wks 2002
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Reifsnyder1 study archive Body weight (several ages), fat mass, body mass index, fat pad weights. QTL population m 4-24wks 2000
Richards-Smith1 study archive
with macronutrient diet option
Caloric intake, glucose, body and fat pad weights. Macronutrient diet option. QTL population m 8-13wks 2002
RIKEN-EAD1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred RBRC   (56) both 8, 12 wks 2008
RIKEN-EAD1 complete blood count Hematology. inbred RBRC   (56) both 8, 12 wks 2008
RIKEN-EAD1 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. inbred RBRC   (56) both 8, 12 wks 2008
RIKEN-EAD2 metabolic panel Clinical blood chemistry (plasma). 4h fast. wild-derived RBRC   (33) both 8, 12 wks 2008
RIKEN-EAD2 complete blood count Hematology. wild-derived RBRC   (33) both 8, 12 wks 2008
RIKEN-EAD2 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. wild-derived RBRC   (33) both 8, 12 wks 2008
Rusyn2 metabolic panel
with trichloroethylene
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. inbred   (17) m 7wks 2010
Rusyn2 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. inbred   (17) m 7wks 2010
Rusyn5 metabolic panel
with high-fat diet and ethanol
Alanine transaminase (serum) after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 alcohol quantification
with high-fat diet and ethanol
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn5 metabolite quantification
with high-fat diet and ethanol
Homocysteine concentration after 4wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn6 metabolic panel
with trichloroethylene
Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 drug and metabolite quantification
with trichloroethylene
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. inbred   (7) m 6-7wks 2014
Schoenrock1 hormone quantification
with various diets
Serum corticosterone at baseline and 10 mins after stress. Comparison of 4 diets. CC RIX   (18) f 8-9 wks 2018
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 lipid profile Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. inbred   (11) both 8-10wks 2005
Schonfeld1 metabolic panel Glucose, beta-hydroxybutyrate (plasma). No fast. inbred   (11) both 8-10wks 2005
Schonfeld1 hormone quantification Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. inbred   (11) both 8-10wks 2005
Schoonjans1 glucose tolerance
with high-fat diet
Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. BXD w/par   (36) m 8-29 wks 2022
Schoonjans1 biomarker quantification
with high-fat diet
Bile acid levels in plasma, feces, and liver. BXD w/par   (36) m 8-29 wks 2022
Schughart4 complete blood count
with influenza A (H3N2) virus
White blood cell count and differentials. Influenza A (H3N2) virus vs. controls. inbred w/CC8   (8) f 8-12wks 2016
Sheehan1 study archive Urinalysis. Creatinine, microalbumin, body weight. QTL population m 10wks 2007
Shockley1 lipid profile
with high-fat diet
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. inbred   (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. inbred   (10) both 10-13wks 2008
Solberg1 study archive Open field test, forced swim test, defensive burying task. QTL population both 11-17wks 2004
Stylianou2 study archive Lipids. Cholesterol, triglycerides, body weight. QTL population both 8-10wks 2006
Su2 study archive
with high-fat diet
Lipids (plasma). Cholesterol, triglycerides, aortic lesions, body mass index. QTL population f 14wks 2009
Svenson3 complete blood count Hematology. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 coagulation test Fibrinogen, anti-thrombin III, factor VIII B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 metabolic panel Glucose, bilirubin, blood urea nitrogen, aspartate transaminase (plasma). 4h fast. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. B6.PWD consomic w/par   (28) both 9wks 2006
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill2 metabolic panel
with acetaminophen
Alanine transaminase (serum). Acetaminophen (several doses) vs. control. inbred   (5) m 6-8wks 2005
Threadgill2 drug and metabolite quantification
with acetaminophen
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). inbred   (5) m 6-8wks 2005
Tomasini1 biomarker quantification Fibronectin. inbred   (25) both 9wks 2007
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Trullas1 hormone quantification Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). inbred   (16) m 6-8wks 1993
Vulpe1 transferrin quantification Diferric transferrin (plasma). inbred   (18) both 8wks 2010
Wang1 study archive
with high-fat diet
Lipids (plasma). Cholesterol, inducibility, triglycerides, atherosclerosis lesions. QTL population f 10-23wks 2003
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wittenburg1 study archive
with high-fat diet
Liver weight, gallbladder and gallstone histopathology. QTL population both 18-20wks 2002
Wittenburg2 study archive
with high-fat diet
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population both 6-16wks 2003
Wittenburg3 study archive
with high-fat diet
Lipids (plasma), liver weight, gallbladder and gallstone histopathology. QTL population both 2005
Xenakis1 drug and metabolite quantification Plasma haloperidol concentration. CC RIX   (73) both 7-13wks 2020
Xenakis2 urinalysis
with arsenic
Urine volume at baseline, and 12 and 24 wks after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolic panel
with arsenic
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 hormone quantification
with arsenic
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolite quantification
with arsenic
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) DO population m 4-34 wks 2022
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Yuan5 study archive Plasma levels of P-selectin and soluble vascular cell adhesion molecule-1. QTL population f 18wks 2008
Zaytseva1 glycosylation profile IgG glycan peaks, relative abundance CC   (111) both 4-140wks 2018
Zaytseva2 glycosylation profile IgG subclasses, relative abundance CC   (95) both 20-117wks 2018
Zhang1 study archive
with western diet
Atherosclerosis and glucose homeostasis. Lesions, lipids, glucose, insulin. High-fat, western-style diet. QTL population f <6-18wks 2012